Alkem Laboratories growth ratios

·Pharma & HealthChart ›
ProfitabilityGrowthCreditLiquidityWorking capitalDividend yieldDuPontCAGR
Per cent unless marked ×
Tap a line for its trendFY26Mar 2026FY25Mar 2025FY24Mar 2024FY22 and earlierAlpha Plus
+13.5%+2.3%+9.2%
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
+19.6%+11.9%+39.5%
+21.7%+10.7%+49.8%
+6.1%+22.3%+79.9%
+6.3%+20.6%+82.5%
+18.0%+13.6%+13.2%
+15.4%+16.0%+13.6%
+2.6%−1.8%+15.8%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

ALKEM₹5,079.00

Alkem Laboratories Ltd.

· Pharma & Health
₹ CrorePeersMANKINDTORNTPHARMIPCALABLUPINFORTISAUROPHARMALAURUSLABSBIOCONMcap ₹60,719 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/06/2026
Revenue Growth—+9.2+2.3+13.5—
EBITDA Growth—+39.5+11.9+19.6—
EBIT Growth—+49.8+10.7+21.7—
Net Income Growth—+79.9+22.3+6.1—
EPS Growth—+82.5+20.6+6.3—
Total Assets Growth—+13.2+13.6+18.0—
Total Equity Growth—+13.6+16.0+15.4—
Cash from Operations Growth—+15.8-1.8+2.6—
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.